Trial Profile
A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Autologous-cancer vaccine-Vaccinogen (Primary)
- Indications Colon cancer
- Focus Registrational; Therapeutic Use
- Acronyms ACTIVE
- Sponsors Vaccinogen
- 14 May 2015 Status changed from planning to recruiting as reported by ClinicalTrials.gov record.
- 23 Feb 2015 New trial record
- 17 Feb 2015 Enrolment is expected to be initiated within 60 days of obtaining adequate funding, according to a Vaccinogen media release.